Relation of Advanced Interatrial Block to Risk of Atrial Fibrillation and Stroke.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 13 12 2019
revised: 26 02 2020
accepted: 27 02 2020
pubmed: 15 4 2020
medline: 29 8 2020
entrez: 15 4 2020
Statut: ppublish

Résumé

Advanced interatrial block (A-IAB) has been associated to atrial fibrillation (AF) and ischemic stroke, raising the question as to whether such patients, even when still in sinus rhythm without documented AF, could benefit from oral anticoagulation. AF and A-IAB are both markers of stroke. The anatomical substrate in both is fibrotic atrial cardiomyopathy, resulting in atrial electromechanical dyssynchrony, dysfunction, and left atrial remodelling, that favour blood stasis and hypercoagulation. Under these conditions thrombogenic cascade may be triggered, resulting in systemic embolization. Before proposing oral anticoagulation in the management of selected patients with A-IAB, as is currently recommended in patients with AF and high CHA

Identifiants

pubmed: 32284175
pii: S0002-9149(20)30208-3
doi: 10.1016/j.amjcard.2020.02.034
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1745-1748

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Antoni Bayés-de-Luna (A)

Cardiovascular Research Foundation. Cardiovascular ICCC-Program, Research Institute Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain. Electronic address: abayes@santpau.cat.

Manuel Martínez-Sellés (M)

Department of Cardiology, Hospital Universitario Gregorio Marañon, CIBERCV. Universidad Europea. Universidad Complutense, Madrid, Spain.

Roberto Elosua (R)

Cardiovascular Epidemiology and Genetics Research Group, REGICOR Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Catalonia, Spain; CIBER Cardiovascular, Barcelona, Catalonia, Spain; Medicine Department, Medical School, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Catalonia, Spain.

Antoni Bayés-Genís (A)

Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, and Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain.

Guiomar Mendieta (G)

Cardiology, Cardiovascular Institute, Hospital Clínic, Barcelona, Spain.

Adrian Baranchuk (A)

Division of Cardiology, Kingston Health Sciences Center, Kingston, Ontario, Canada.

Günter Breithardt (G)

Department of Cardiovascular Medicine, Division of Rhythmology, University Hospital Münster, Münster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH